Literature DB >> 21567198

Expression, purification and characterization of low-glycosylation influenza neuraminidase in α-1,6-mannosyltransferase defective Pichia pastoris.

Yi-Li Yang1, Shao-Hong Chang, Xin Gong, Jun Wu, Bo Liu.   

Abstract

Influenza A viruses expose two major surface glycoproteins, hemagglutinin (HA) and neuraminidase (NA). Although N-glycosylation is essential for many glycoproteins, the glycoproteins expressed in yeast are sometimes hyper-glycosylated, which maybe a primary hindrance to the exploitation of therapeutic glycoprotein production because glycoproteins decorated with yeast-specific glycans are immunogenic and show poor pharmacokinetic properties in humans. To elucidate the NA with different glycosylation in interaction with immunogenicity, here we reported the heterologous expression of influenza NA glycoprotein derived from influenza virus A/newCaledonia/20/99(H1N1) in wide-type Pichia pastoris, α-1,6-mannosyltransferase (och1)-defective P. pastoris and Escherichia coli. We also assessed the immunogenicity of hyper-glycosylated NA expressed in the wide-type, low-glycosylated NA expressed in och1-defective P. pastoris strain and non-glycosylated NA produced in E. coli. Recombinant NA was expressed in wide-type P. pastoris as a 59-97 above kDa glycoprotein, 52-57 kDa in the och1 defective strain, and as a 45 kDa non-glycoprotein in E. coli. The antibody titers of Balb/c mice were tested after the mice were immunized three times with 0.2, 1, or 3 μg purified recombinant NA. Our results demonstrated that after the second immunization, the antibody titer elicited with 1 μg low-glycosylated NA was 1:5,500, while it was 1:10 and 1:13 when elicited by 1 μg hyper-glycosylated and non-glycosylated NA. In the 0.2 μg dose groups, a high antibody titer (1:4,900) was only found after third immunization by low-glycosylated NA, respectively. These results suggest that low-glycosylation in och1-defective P. pastoris enhances the immunogenicity of recombinant NA and elicits similar antibody titers with less antigen when compared with hyper- and non-glycosylated NA. Thus, och1-defective P. pastoris may be a better yeast expression system for production of glycoproteins to research immunogenic characterization.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21567198     DOI: 10.1007/s11033-011-0809-z

Source DB:  PubMed          Journal:  Mol Biol Rep        ISSN: 0301-4851            Impact factor:   2.316


  36 in total

1.  The oligosaccharides of influenza virus hemagglutinin expressed in insect cells by a baculovirus vector.

Authors:  K Kuroda; H Geyer; R Geyer; W Doerfler; H D Klenk
Journal:  Virology       Date:  1990-02       Impact factor: 3.616

2.  Use of combinatorial genetic libraries to humanize N-linked glycosylation in the yeast Pichia pastoris.

Authors:  Byung-Kwon Choi; Piotr Bobrowicz; Robert C Davidson; Stephen R Hamilton; David H Kung; Huijuan Li; Robert G Miele; Juergen H Nett; Stefan Wildt; Tillman U Gerngross
Journal:  Proc Natl Acad Sci U S A       Date:  2003-04-17       Impact factor: 11.205

3.  Monosaccharide compositions of Danaus plexippus (monarch butterfly) and Trichoplusia ni (cabbage looper) egg glycoproteins.

Authors:  Y I Park; H A Wood; Y C Lee
Journal:  Glycoconj J       Date:  1999-10       Impact factor: 2.916

4.  Specific subtyping of influenza A virus using a recombinant hemagglutinin protein expressed in baculovirus.

Authors:  Shahla Shahsavandi; Ali-Hatef Salmanian; Seyed Ali Ghorashi; Shahin Masoudi; Fatemeh Fotouhi; Mohammad Majid Ebrahimi
Journal:  Mol Biol Rep       Date:  2010-11-26       Impact factor: 2.316

Review 5.  Heterologous protein production using the Pichia pastoris expression system.

Authors:  Sue Macauley-Patrick; Mariana L Fazenda; Brian McNeil; Linda M Harvey
Journal:  Yeast       Date:  2005-03       Impact factor: 3.239

6.  Production in Pichia pastoris and characterization of genetic engineered chimeric HBV/HEV virus-like particles.

Authors:  Hong-Zhao Li; Hong-Ying Gang; Qiang-Ming Sun; Xiao Liu; Yan-Bing Ma; Mao-Sheng Sun; Chang-Bai Dai
Journal:  Chin Med Sci J       Date:  2004-06

7.  Expression, purification and characterization of recombinant human interleukin-22 in Pichia pastoris.

Authors:  Xin Cai; Jinfeng Wang; Yuanyuan Wang; Yongchang Yang; Jie Gao; Wenliang Fu; Jiaxi Wang; Donggang Xu
Journal:  Mol Biol Rep       Date:  2009-09-16       Impact factor: 2.316

8.  Recombinant neuraminidase vaccine protects against lethal influenza.

Authors:  T Deroo; W M Jou; W Fiers
Journal:  Vaccine       Date:  1996-04       Impact factor: 3.641

9.  Expression and characterization of HPV-16 L1 capsid protein in Pichia pastoris.

Authors:  Silvia Boschi Bazan; Agtha de Alencar Muniz Chaves; Karina Araújo Aires; Aurora Marques Cianciarullo; Robert L Garcea; Paulo Lee Ho
Journal:  Arch Virol       Date:  2009-09-10       Impact factor: 2.574

10.  Detection of the lipid-linked precursor oligosaccharide of N-linked protein glycosylation in Drosophila melanogaster.

Authors:  G F Parker; P J Williams; T D Butters; D B Roberts
Journal:  FEBS Lett       Date:  1991-09-23       Impact factor: 4.124

View more
  13 in total

1.  Evaluation of antibody response in mice against avian influenza A (H5N1) strain neuraminidase expressed in yeast Pichia pastoris.

Authors:  Murugan Subathra; Ponsekaran Santhakumar; Mangamoori Lakshmi Narasu; Syed Sultan Beevi; Sunil K Lal
Journal:  J Biosci       Date:  2014-06       Impact factor: 1.826

2.  Vaccines to combat river blindness: expression, selection and formulation of vaccines against infection with Onchocerca volvulus in a mouse model.

Authors:  Jessica A Hess; Bin Zhan; Sandra Bonne-Année; Jessica M Deckman; Maria Elena Bottazzi; Peter J Hotez; Thomas R Klei; Sara Lustigman; David Abraham
Journal:  Int J Parasitol       Date:  2014-06-05       Impact factor: 3.981

3.  A simple Pichia pastoris fermentation and downstream processing strategy for making recombinant pandemic Swine Origin Influenza a virus Hemagglutinin protein.

Authors:  T N Athmaram; Anil Kumar Singh; Shweta Saraswat; Saurabh Srivastava; Princi Misra; M Kameswara Rao; N Gopalan; P V L Rao
Journal:  J Ind Microbiol Biotechnol       Date:  2012-12-18       Impact factor: 3.346

Review 4.  In the shadow of hemagglutinin: a growing interest in influenza viral neuraminidase and its role as a vaccine antigen.

Authors:  Teddy John Wohlbold; Florian Krammer
Journal:  Viruses       Date:  2014-06-23       Impact factor: 5.048

5.  Development of a fed-batch process for a recombinant Pichia pastoris Δoch1 strain expressing a plant peroxidase.

Authors:  Christoph Gmeiner; Amirhossein Saadati; Daniel Maresch; Stanimira Krasteva; Manuela Frank; Friedrich Altmann; Christoph Herwig; Oliver Spadiut
Journal:  Microb Cell Fact       Date:  2015-01-08       Impact factor: 5.328

6.  Characterization and immunological activity of different forms of recombinant secreted Hc of botulinum neurotoxin serotype B products expressed in yeast.

Authors:  Bo Liu; DanYang Shi; ShaoHong Chang; Xin Gong; YunZhou Yu; ZhiWei Sun; Jun Wu
Journal:  Sci Rep       Date:  2015-01-08       Impact factor: 4.379

7.  Influenza Neuraminidase Subtype N1: Immunobiological Properties and Functional Assays for Specific Antibody Response.

Authors:  Don Changsom; Hatairat Lerdsamran; Witthawat Wiriyarat; Warunya Chakritbudsabong; Bunpote Siridechadilok; Jarunee Prasertsopon; Pirom Noisumdaeng; Wanibtisam Masamae; Pilaipan Puthavathana
Journal:  PLoS One       Date:  2016-04-07       Impact factor: 3.240

8.  Effects of Rho1, a small GTPase on the production of recombinant glycoproteins in Saccharomyces cerevisiae.

Authors:  Sha Xu; Ge-Yuan Zhang; Huijie Zhang; Toshihiko Kitajima; Hideki Nakanishi; Xiao-Dong Gao
Journal:  Microb Cell Fact       Date:  2016-10-21       Impact factor: 5.328

9.  Systematic assessment of Pichia pastoris system for optimized β -galactosidase production.

Authors:  Hongbing Sun; Olufemi Emmanuel Bankefa; Ijeoma Onyinyechi Ijeoma; Liangtian Miao; Taicheng Zhu; Yin Li
Journal:  Synth Syst Biotechnol       Date:  2017-04-25

10.  Recombinant horseradish peroxidase variants for targeted cancer treatment.

Authors:  Günther Bonifert; Lisa Folkes; Christoph Gmeiner; Gabi Dachs; Oliver Spadiut
Journal:  Cancer Med       Date:  2016-03-15       Impact factor: 4.452

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.